Drugs / CX157
CX157
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01633437 | Sep → Oct 2010 | major depressive disorder | CeNeRx BioPharma Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01246908 | Nov 2010 → May 2012 | — | CeNeRx BioPharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00739908 | Sep 2008 → Jul 2009 | major depressive disorder | CeNeRx BioPharma Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739908 ↗ |
| Known as | KP157 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802137 ↗ |
| Known as | TriRima | “CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)” NCT01246908 ↗1“CX157 (TriRima) 60mg Three Times a Day (TID)” NCT00739908 ↗ |
| Known as | Tyrima | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802137 ↗ |
| Action | Inhibit | “CX157 is a reversible monoamine oxidase inhibitor (RIMA)” NCT01633437 ↗ |
| Modality | Small molecule | — CHEMBL4802137 ↗ |
| Route | Oral | “Oral Tyramine Pressor Response Study of CX157 Tablets” NCT01633437 ↗ |